ASLAN Pharmaceuticals Lim... (ASLN)
0.60
-0.10 (-14.27%)
At close: Jul 18, 2024, 8:00 PM
0.56
-6.67%
After-hours: Jul 18, 2024, 07:58 PM EDT
-14.27% (1D)
| Bid | 0.56 |
| Market Cap | 1.7M |
| Revenue (ttm) | 12M |
| Net Income (ttm) | -35.03M |
| EPS (ttm) | -16 |
| PE Ratio (ttm) | -0.0375 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.63 |
| Volume | 769,822 |
| Avg. Volume (20D) | 102,493 |
| Open | 0.63 |
| Previous Close | 0.70 |
| Day's Range | 0.60 - 0.70 |
| 52-Week Range | 0.47 - 17.04 |
| Beta | 1.40 |
About ASLN
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a ...
Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2018
Employees 35
Stock Exchange NASDAQ
Ticker Symbol ASLN
Website https://aslanpharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ASLN stock is "Buy." The 12-month stock price forecast is $72, which is an increase of 11900.00% from the latest price.
Stock Forecasts9 months ago
-36.94%
ASLAN Pharmaceuticals shares are trading lower aft...
Unlock content with
Pro Subscription
9 months ago
-45.88%
ASLAN Pharmaceuticals shares are trading lower after the company announced the receipt of a Nasdaq delisting determination.